Comparative Pharmacology
Head-to-head clinical analysis: DYANAVEL XR 20 versus METADATE CD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYANAVEL XR 20 versus METADATE CD.
DYANAVEL XR 20 vs METADATE CD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DYANAVEL XR is a central nervous system (CNS) stimulant. The mode of action is primarily through blockade of the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their levels in the extraneuronal space. It also releases these monoamines from storage sites. The dextroamphetamine component is more potent than amphetamine in inhibiting norepinephrine reuptake, while the amphetamine component is more potent in inhibiting dopamine reuptake.
Methylphenidate is a central nervous system (CNS) stimulant. It blocks the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their levels in the extraneuronal space. The precise mechanism for treating ADHD is not fully understood.
Initial 20 mg orally once daily in the morning, with or without food; may increase by 10 mg weekly to maximum 60 mg/day.
20-60 mg orally once daily in the morning
None Documented
None Documented
Terminal elimination half-life: 6-8 hours (stable metabolite). Clinical context: Twice-daily dosing typical due to pharmacokinetic profile; extended half-life compared to immediate-release amphetamine.
Terminal elimination half-life: 6.8 hours (range 4.5-10.3 hours) for methylphenidate; clinical context: supports twice-daily dosing regimen
Renal: 90% (unchanged drug and metabolites, primarily hippuric acid). Fecal/biliary: <1%.
Renal: 78-97% as metabolites (primarily ritalinic acid), unchanged drug <1%; fecal: <2%
Category C
Category C
CNS Stimulant
CNS Stimulant